Live Breaking News & Updates on Cardiovascular disease database

Stay informed with the latest breaking news from Cardiovascular disease database on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Cardiovascular disease database and stay connected to the pulse of your community

Ultra-processed: Five foods you should avoid to protect heart health

Two years ago, the British Heart Foundation declared the country was in “the grip of the worst heart care crisis in living memory” as 39,000 people in...

Spain , United-kingdom , Australia , Britain , British , Australian , Jeff-siepman , Neil-srinivasan , British-heart-foundation , Red-bull , United-kingdom-heart-clinic , Ultraprocessed

J&J paces interventional cardio market with $13B Shockwave buy

Med-tech powerhouse Johnson & Johnson made a bold bid to bolster its interventional cardiology holdings with the news on April 5 that it is acquiring Shockwave Medical Inc. for approximately $13.1 billion including cash acquired. The $335 per share cash price represents a more than 5% premium to Shockwave’s (Nasdaq: SWAV) April 4 closing price and a more than 17% premium to the stock price prior to the Wall Street Journal report last week about the rumoured deal.

Shockwave-medical-inc , Johnson , Shockwave-medical , Wall-street-journal , Deals-andm-amp-a , Bioworld-medtech , Cardiovascular , Johnson-amp , Shockwave-medical-inc- , Coronary-artery-disease , Peripheral-artery-disease

Moderate amounts of alcohol increase heart disease risk in women

A study by Kaiser Permanente Northern California reveals an increased risk of heart disease in young to middle-aged women who consume over one alcohol

Jamals-rana , Kaiser-permanente-division-of-research , American-college-of-cardiology-annual-scientific-session , Permanente-medical-group , Division-of-research , American-college , Annual-scientific-session , Kaiser-permanente-division , Women , Moderate-alcohol-intake , Heart-disease-risk

Short-Term Biofeedback Therapies Lead to Alleviation of Certain Long COVID Symptoms

The investigators seek to replicate the data in a future randomized control trial, and they hope to compare biofeedback to different therapies such as pulmonary rehabilitation.

Natachad-emerson , Journal-of-psychosomatic-research , Psychiatry-biobehavioral-sciences , Psychiatry-biobehavioral-sciences-natachad-emerson , David-geffen-school-of-medicine , Vasc-health-risk-manag , Biobehavioral-sciences , David-geffen-school , Its-cardiovascular-consequences-during , Vasc-health-risk , Covid-19

Novo nabs Cardior in €1B deal, gaining phase II-stage miRNA drug

In what co-founder and CEO Claudia Ulbrich called the “right decision with right partner at the right point in time,” Cardior Pharmaceuticals GmbH agreed to an acquisition by Novo Nordisk A/S in a deal worth up to €1.025 billion (US$1.1 billion) that puts a potentially disease-modifying heart failure candidate in the hands of a big pharma player in the midst of establishing its presence in cardiovascular disease.

Claudia-ulbrich , Novo-nordisk , Cardior-pharmaceuticals-gmb , Pharmaceuticals-gmbh , Novo-nordiska-s , Cardior-pharmaceuticals-gmbh , Cdr-132l , Heart-disease , Mir-132 , Mirna , Bioworld

FDA Expands Labels for Nexletol, Nexlizet to Prevent Heart Attacks and Cardiovascular Procedures

This expansion applies to the estimated 70 million patients who need either primary or secondary prevention, regardless of statin use.

Sheldon-koenig , European-medicines-agency , Committee-for-medicinal-products-human , Esperion-therapeutic , Olivier-le-moal , Medicinal-products , Cardiovascular , Heart-attack , Fda-approval , Nexletol , Nexlizet ,

Biosense Webster continues PFA approval trend, nabs CE mark for Varipulse

Continuing the spate of regulatory approvals for pulsed field ablation (PFA) devices around the world, Johnson & Johnson’s Biosense Webster Inc. unit secured CE mark for the Varipulse platform for treatment of symptomatic, drug-refractory recurrent paroxysmal atrial fibrillation.

Johnson-biosense-webster-inc , Biosense-webster , Bioworld-medtech , Biosense-webster-inc- , Us- , Ce-mark , Johnson-amp , Boston-scientific-corp- , Medtronic-plc , Farapulse-inc- , Varipulse

First heart centre set up in Eldoret amid rising cardiovascular cases

First heart centre set up in Eldoret amid rising cardiovascular cases

Nairobi , Nairobi-area , Kenya , Eldoret , Rift-valley , Felix-barasa , Moi-university , Moi-teaching , Referral-hospital , Heart-disease , Cardiovascular , Heart-attadck

There Is No Interaction Between BMI and SGLT2 Inhibitor Efficacy in HF, Review Finds

Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.

United-states , American , Wolfram-doehner , Olivier-le-moal , American-journal , Managed-care , Intern-emerg , Eurj-heart , Heart-fail , Heart-failure , Cardiovascular

February is Heart Health Awareness Month

Lisa Stringfield stood in front of a crowd giving a speech when she felt something unusual in her arms, chest, and neck.

United-states , America , Lisa-stringfield , Scott-cook-at-baptist-health-richmond , Heart-health-awareness-month , Heart-health-awareness , Scott-cook , Baptist-health , February , Awarness , Cardiovascular , Disease